Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma
Liver International · 2025
DOI: 10.1111/liv.70066 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Rong Li und 17 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, N…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Liver Neoplasms, Viremia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Science and Technology Projects in Guangzhou, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background and Aims The impact of low‐level viremia(LLV) on the efficacy of immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma(uHCC) patients remains unclear. This study aims to investigate the effect of LLV on the outcomes of ICIs‐based therapy in patients with uHCC.
Methods
In this multicenter retrospective study, we included patients with uHCC who received ICIs‐based therapy at four centres between January 2019 and December 2022. All patients were positive for HBsAg and were on nucleos(t)ide analogues (NAs) antiviral therapy. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were used to balance baseline characteristics between the LLV and maintained virological response (MVR) groups. Proteomic analysis was performed on a subset of patients to identify differential protein expression.
Results
A total of 329 patients (mean age 56 years; 92.4% male; 70.8% BCLC stage C) were included, with 170 patients in the LLV group and 159 in the MVR group. The objective response rate (ORR) was significantly lower in the LLV group compared to the MVR group (21.2% vs. 36.5%, p = 0.002), as was the disease control rate (DCR) (78.8% vs. 92.5%, p < 0.001). Median progression‐free survival (mPFS) was shorter in the LLV group (7.6 vs. 12.6 months, p < 0.001), as was median overall survival (mOS) (22.8 vs. 40.0 months, p < 0.001). These differences remained consistent after PSM and IPTW adjustments. Multivariate analysis identified LLV as the only independent risk factor for overall survival (hazard ratio [HR] 0.522, 95% CI 0.348–0.781; p = 0.002). Proteomic analysis revealed significant differences in the expression of Flt3L, SLAMF1 and FGF‐5 proteins between the LLV and MVR groups.
Conclusion
LLV is associated with poorer responses to ICIs‐based therapy and reduced survival in patients with HBV‐related uHCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, Pe…
- Department of Respiratory Medicine, The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan, People's Republic of China.
- Department of Infectious Diseases, Zhuhai People's Hospital, Zhuhai, Guangdong, People's Republic of China.
- Department of Hepatology, Guangzhou Eighth People's Hospital Affiliated to Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
- Department of Hepatology, Huizhou Central People's Hospital, Huizhou, Guangdong, People's Republic of China.
ORCID-Profile: Yujuan Guan, Guosheng Yuan, Jinzhang Chen
Förderung
- National Key Research and Development Program of China
- Science and Technology Projects in Guangzhou
- National Natural Science Foundation of China
Zitieren
APA
Li, R., Li, W., Yang, Q., Guan, Y., Chen, Y., Zhu, P., Su, K., Li, Q., Hu, X., Zang, M., Zhao, M., Zhong, M., Yan, J., Yang, K., Zhu, W., Lin, Z., Yuan, G., & Chen, J. (2025). Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma. Liver International. https://doi.org/10.1111/liv.70066
Vancouver
Li R, Li W, Yang Q, Guan Y, Chen Y, Zhu P, et al. Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma. Liver International. 2025. doi:10.1111/liv.70066
BibTeX
@article{Li2025,
author = {Li, Rong and Li, Wenli and Yang, Qing and Guan, Yujuan and Chen, Yongru and Zhu, Peilin and Su, Kaiyan and Li, Qi and Hu, Xiaoyun and Zang, Mengya and Zhao, Miaoxian and Zhong, Manhua and Yan, Jingquan and Yang, Keli and Zhu, Wei and Lin, Zhanzhou and Yuan, Guosheng and Chen, Jinzhang},
title = {Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70066}
}
EUVIMED